Introduction
Hematopoietic SCT (HSCT) is the standard of care for an increasing number of malignant and non-malignant hematological disorders. 1 However, the individual indication for a patient to undergo HSCT has to be carefully balanced against the risk of developing severe complications associated with the procedure. Although, there have been advances in the management of complications in recent years TRM remains a significant problem in up to 27% of the patients. 2 In total, 15-40% of patients receiving a HSCT have to be submitted to the intensive care unit (ICU) because of a variety of reasons. 3 Respiratory failure (RF) is the leading cause of the deterioration of patients' conditions after transplant. In a recently published meta analysis Bach et al. 4 showed that RF and mechanical ventilation (MV) are associated with an extremely poor prognosis of the patients. The authors described that the median time from transplant to MV is 27 days indicating that the early post-engraftment phase is critical for the patients. A number of risk factors have been described for the development of this complication, including non-T-cell depleted transplant regimens, a reduced pretransplant forced expiratory volume 1 and TBI. 5, 6 However, it is still difficult to assess the individual risk for RF leading to therapeutical consequences in the preparative regimen for HSCT.
Only recently, Pene et al. 7 described their experience with a large cohort of patients undergoing HSCT. They concluded that patients who developed RF late after HSCT have a dismal prognosis. Moreover, they reported that patients in whom MV could be withheld had a significantly higher ICU discharge and survival rate. This could be either due to less severe lung damage after transplant or due to the efficacy of supportive care including non-invasive ventilation (NIV). The latter point has been challenged in a study by Hilbert et al.
impact of early NIV administered on standard care hematology wards to prevent worsening of RF and MV after allogeneic HSCT.
Patients, materials and methods

Patients
From December 2001 to August 2005 all adult allogeneic HSCT recipients admitted to the hematological transplant unit of the University Hospital Dresden were routinely monitored for respiratory rate, OI and peripheral oxygen saturation. OI was determined by a capillary blood gas analysis (while the patient breathing room air) starting at the beginning of the conditioning regimen and was calculated as ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (OI ¼ paO 2 /FiO 2 ). The experimental protocol was approved by the local institutional review board and all patients participating in the randomized trial gave written informed consent. Clinical charts were reviewed by two observers (MW and SS).
Experimental protocol
The following criteria were regarded as signs of respiratory distress: a respiratory rate 425/min, OI o300 or a continuous oxygen saturation o92% while breathing room air. The presence of two of these criteria was accepted as an acute lung injury condition, which we refer to as RF and lead to enrollment of the patient. For the exclusion of cardiac origin of respiratory distress, left ventricular failure function was assessed by echocardiography investigation within 24 h after onset of the symptoms. To secure patient safety in a trial based on normal hematology/ transplant wards further criteria were defined to exclude patients in immediate need for transfer to the ICU: need for emergency intubation, hemodynamic instability (defined as the need for vasopressor support), left ventricular failure with consecutive pulmonary edema or neurologic deterioration with a Glasgow Coma Scale below 8. Eligible Patients were randomized to receive oxygen supply (arm A) or oxygen supply plus intermittent NIV (arm B). Randomization was based on a computer generated balanced (block wise) randomization list. A person not involved in the clinical trial provided the randomized treatment allocation to the treating physicians. Patients who did not fulfill either inclusion nor exclusion criteria were followed as controls. After randomization a diagnostic work up had to be carried out as soon as possible (latest within the next 24 h) comprising: high-resolution computed tomographic-chest scan or at least conventional chest X-ray, echocardiography. In case of proven infiltrates as suggested by computed tomography a bronchoscopy including bronchoalveolar lavage was conducted. Routine evaluation of bronchoalveolar lavage included microscopy and culture for bacteria and fungi, as well as assessment for pneumocystis, toxoplasmosis, chlamydia, mycoplasma and tuberculosis. Specific tests for aspergillus or viral infections were performed only when demanded by the treating physician.
Patients randomized to arm A received oxygen via nasal insufflation or full face mask starting at a dose of 3 L/min. Adjustment of oxygen flow was left to the treating physician's discretion. Individuals in arm B also remained in standard care hematology wards and were treated with intermittent NIV via a full-face mask (Air Cushion Mask w/Valve, Hsiner, Shengang, Taiwan) using respirators designed for homecare ventilation (VS-Integra, Saime, Savigny le Temple France/Respicare SC, Dra¨ger, Luebeck, Germany). Ventilation therapy was provided by hematology nurses and physicians. At the start of treatment, positive end-exspiratory pressure was set to 7 mbar and pressure support to 15 mbar. Later these values were adjusted according to patient tolerance and capillary blood gas analysis. NIV should be administered intermittently for at least 30 min every 3 h. Response was assessed twice daily by monitoring OI, SpO2 and respiratory rate. Failure was defined in both arms as the presence of one of the following three criteria: (1) OI below 300, (2) SpO 2 o92% or (3) respiratory rate 425/min. Furthermore, patients requiring immediate intensive care treatment were regarded as failing to improve on the assigned therapy.
Because of recent reports arguing for a benefit of early NIV in allogeneic HSCT recipients 8 patients failing in treatment arm A were not immediately transferred to ICU but allowed to cross over to NIV after 12 h of receiving oxygen. If the assigned treatment strategy or crossing over did not lead to respiratory improvement as defined by the failure criteria patients were referred to ICU. At the ICU treatment was continued using NIV under intensive care conditions. A restrictive strategy for intubation was defined as follows: intubation only if OI o100, SpO 2 o85% in spite of NIV and respiratory acidosis (pH o7.25). Furthermore, severe encephalopathy (Glasgow Coma Scale o8), the presence of hemodynamic shock with systolic blood pressure below 70 mm Hg, increased likelihood of aspiration or progressive aerophagy were regarded as indication for MV. MV was performed following the recommendations for protective ventilation (http://www.ardsnet.org).
Data collection and statistical analysis
The following demographic variables, hematologic diseaseand transplantation-related characteristics were collected: age, sex, underlying hematologic disease and its status at transplantation, conditioning regimen, source of stem cells, and type of transplantation.
The primary endpoint for the randomized trial was the difference in 100-day mortality rates between control and NIV-treated patients as assessed by the log-rank test. The number of patients required was calculated based on the log-rank test with type 1 error set to 5% and a statistical power of 80%. 9 On the basis of the data presented by Hilbert et al. 8 the working hypothesis was that NIV would lower 100-day mortality from 80 to 50%. Under these premises a total of 39 patients had to be included in each treatment arm. Considering a drop-out rate of 10% the total sample size was set to 86 patients. Secondary survival endpoints were long-term overall survival (OS) and time to treatment failure. For the latter, treatment failure was defined as combined endpoint of switch to NIV-ventilation (arm A only) or transfer to ICU or intubation or death. All analyses were done using SPSS software 15.0 (SPSS-IBM, Ehningen, Germany). Survival was calculated using the Kaplan-Meier method. Differences were calculated using the log-rank test. Continuous variables were compared by Mann-Whitney U-test, whereas categorical characteristics were assessed by the Fishers-exact test or w 2 test as appropriate. All tests were two-sided and a P-value below 0.05 was regarded as significant. Correlations between patient characteristics and mortality were assessed using multivariate Cox regression models.
Results
RF is an independent risk factor for shortened OS in patients undergoing allo-SCT During the study period, 530 patients underwent allogeneic transplantation in our department. In these patients breathing rate, peripheral oxygen saturation and OI were routinely assessed twice daily. During the study period 90 patients fulfilled inclusion criteria. Four patients refused to participate in the interventional study and were therefore not eligible. Patient characteristics are listed in Table 1 . Median time to onset of RF was 10 days post-HSCT. Therefore, the majority of the participants (64/86; 74.4%) suffered from severe neutropenia at the time of inclusion.
Most of the patients (n ¼ 79-92%) were assessed as having RF by the OI o300 threshold in combination with one other criterion (peripheral oxygen saturation or breathing rate above 25/min). Only, seven patients demonstrated OI 4300 but fulfilled the two other criteria for the definition of RF. Interestingly, tachypnea was quite uncommon in patients suffering from RF after HSCT, with only eight patients having a respiratory rate exceeding 25/min.
We next thought to determine whether the occurrence of RF was related to clinical characteristics of the affected patient population. Therefore, we compared the clinical characteristics of the two patient groups (Table 1) . Thereby, high-dose TBI, defined as application of 8 Gy or more, as part of the conditioning regimen was significantly more frequent in the RF cohort. Subsequently, the impact of TBI and increased age could be demonstrated in a multivariate analysis as independent risk factors for the occurrence of RF in patients after HSCT (Supplementary Table 1 ).
To elucidate the etiology of RF a diagnostic computed tomographic-scan was done in 79 of 86 patients. In the remaining seven patients, disease severity or technical problems precluded transport to the radiology department and a bedside X-ray was taken instead. Radiographic imaging was normal or non-informative in 17 patients. Atypical infiltrates were the most common diagnosis found in 36 of 86 (41.9%) patients, followed by signs of active aspergillosis (14/86; 16.3%) and pleural effusions or signs of fluid overload (11/86; 12.8%). Only four patients presented with signs of lobar pneumonia, whereas one patient had a mantle pneumothorax, which was not considered to be the underlying cause of RF. Bronchoscopy with bronchoalveolar lavage was performed in 41 patients at a median of 1 day after diagnosis of RF. Procedure-related adverse events occurred in none of these patients. Microbiologic assessment was normal or demonstrated upper respiratory tract commensals in 32 (78.0%) patients. In the remaining patients the following bacteria were detected: pseudomonas species (n ¼ 2), enterocci (n ¼ 2), stenotrophomonas (n ¼ 1) and hemolysing streptococci group C (n ¼ 1). Infection with aspergillus, toxoplasmosis and Pneumocystis jirovecii was diagnosed in one patient each. PCR was positive for at least one viral nucleic acid in 24 of 34 (70.6%) assessed patients. Only in six patients was the Respiratory failure in patients undergoing allogeneic hematopoietic SCT M Wermke et al detected virus considered to be related to the occurrence of RF (CMV, respiratory syncytial virus and parainfluenza virus each n ¼ 2). Next, we set out to define the impact of RF on survival after HSCT. Patients suffering from RF showed significantly shortened 100-day survival (RF 65% vs controls 85%, Po0.001-data not shown). The observed differences in 100-day survival translated into reduced long-term OS and significantly increased cumulative incidence of TRM ( Figure 1) .
Next, we performed multivariate analysis to prove an independent effect of RF on survival after allogeneic transplantation. The analysis was performed for 100-day and long-term OS, including the variables RF, acute GvHD III and IV, disease status at transplantation, use of TBI, type of conditioning and the presence of human leukocyte antigen-mismatch as possible factors influencing prognosis. Using cox-regression analysis RF was a strong independent adverse prognostic factor affecting short and long-term OS beside advanced stage of disease at time of transplantation and acute GvHD grade III and IV (Table 2) .
Thus, we conclude that RF in the early post-transplant period is an independent risk factor for survival after HSCT.
Results of a randomized trial of NIV vs oxygen application
Of the 86 patients consenting to participate in the trial of early interventional NIV 44 patients were randomized to arm A (control) and 42 patients to arm B (NIV). Both groups were well balanced regarding patient, disease and treatment-related characteristics (Table 3) .
After the diagnosis of RF, patients were immediately randomized into two treatment arms. As can be seen in Figure 2 both treatment approaches were followed by a rapid improvement of oxygenation. There was no advantage of NIV treatment with respect to an improved OI after 12 and 36 h, respectively. However, treatment failure defined as either inability to achieve OI values 4300, a peripheral oxygen saturation below 92% or breathing rate above 25/min, was more frequent in patients treated on arm A, but this difference did not reach statistical significance (arm A: 17 out of 44 patients ¼ 39% vs arm B: 10 out of 42 Short-and long-term survival were similar between both groups (100-day OS arm A 68% vs arm B 61%; see also Figure 3 ). There was further no significant difference in terms of time-totreatment-failure (data not shown). However, it must be noted that of the 17 patients failing on arm A, 16 crossed over to arm B, which may impair analyses of outcomes after ICU admission.
Using multivariate analysis, only disease status at transplantation and human leukocyte antigen mismatch could be identified as risk factors for shortened 100-day and long-term OS (Table 4 ). Aspergillosis at the time of transplantation (possible, probable or certain) was not associated with dismal prognosis. The 100-day OS in the 17 Table 3 Characteristics of ALI patients enrolled in the trial of early intervention Comparison of disease and treatment characteristics of patients in arm A (oxygen) and B (NIV). Absolute nos. are given first, percentages can be found in brackets. HLA match means 10 out of 10 alleles (HLA-A, -B, -Cw, DRB-1 and DQB-1). In case of equal CMV status in donor and recipient, CMV was designated 'match' whereas all other situations were marked 'mismatch'. Steroiddependent GvHD was defined as post-transplant skin, liver or gut reactions requiring X1 mg/kg prednisolone. Aspergillosis was defined when probable aspergillosis as evidenced by chest CT scan was evident. The presence of bipulmonary infiltrates was assessed using chest X-ray or CT scan. patients with preexisting aspergillosis was similar to that of the remaining patients without this precondition (70.6 vs 63.8%; P ¼ 0.600). Additionally, signs of active aspergillosis at time of inclusion did not negatively impact on 100-day OS (aspergillosis: 57.1% vs no aspergillosis 66.7%; P ¼ 0.353).
Finally, we performed a multivariate analysis to identify factors associated with adverse outcome (as defined by the need for ICU admission). Among patients suffering from RF after transplant no single parameter could be shown to predict for ICU transfer (see Supplementary Table 2 ).
Discussion
Complications of the respiratory system are the most common problems encountered after allogeneic transplantation occurring in 15-30% of the patients. 4 Moreover, several studies reported that severe RF leading to ICU treatment and intubation is associated with a dramatic decrease in survival rates. [10] [11] [12] Given the severity of this complication after allogeneic transplantation it is surprising that it is neither known how to define early signs of respiratory dysfunction nor whether those signs account for the later development of severe lung injury. The current study investigated a combination of clinical signs to indicate a patient population at risk for the development of lung injury after HSCT. Here, we describe the determination of the OI as a powerful tool not only for the definition of RF but also as an independent risk parameter for OS and TRM.
So far, most studies characterized pretransplant characteristics such as age, the forced expiratory volume 1 before transplantation or characteristics related to the transplant regimen (for example, TBI or T-cell depletion) to assess the risk to develop RF. 5, 6 In support of these data we have seen an association between the application of TBI and increased age and RF. However, we did not find additional clinical characteristics associated with the occurrence of RF. This is further evidence that the development of RF is a complex process involving toxic, infectious and inflammatory mechanisms, which may be even diversified by host susceptibility factors.
In our study, RF was defined by the exclusion of cardiac disease and two respiratory criteria. For reasons of practicability and anticipated time delay for the intervention we did not define pulmonary infiltrates as suggested by Bernard et al. 13 as entry criteria for the study. Thus, we believe that our approach is the earliest possibility to detect lung injury after allogeneic transplantation. Under this conditions RF turned out to be an independent risk factor and should therefore guide the treating physician to a better supportive care in a risk population.
It is generally accepted, that an early intervention in the case of hypoxemic acute RF is useful to avoid more severe complications, such as intubation and MV, in a variety of clinical situations. [14] [15] [16] Hilbert et al. 8 were first to describe a protective impact of the application of early NIV in immunocompromised patients. However, in their study the term ''immunocompromised'' was based on a heterogenous patient population mostly undergoing chemotherapy for hematological cancers but rarely (about 30%) involving patients after transplantation. In our patient population we could not detect statistical association between the early application of NIV and improved outcome after transplantation. Thus, validation of the findings by Hilbert et al. of a positive effect of early NIV application has failed, which may be in part due to a different patient selection. Nonetheless, we have seen also positive effects of the application of early NIV in stem cell recipients because there were only 14% of the patients randomized to the NIV treatment arm who had to be intubated as compared with 25% of patients randomized to oxygen only. Although this difference is not statistically significant we consider it to be important given the crossover design of the study allowing for switch of the therapy arm A-B in case of persistent RF. Moreover, it has to be noted that almost all patient randomized to oxygen (arm A) when being transferred to ICU had to be intubated (11 out of 12), whereas only 6 out of the 10 patient transferred to ICU in the NIV treatment arm were intubated, indicating that early NIV can have protective effects in this patient population. Our study has limitations, which should be indicated. In principal the study investigated only ''very early'' intervention differences between oxygen supply and NIV after allogeneic transplantation. Later differences will be obscured by the trial design and the opportunity for the patients to switch therapy arm. However, we considered this design acknowledging data showing benefit for NIVtreated hypoxemic patients in other clinical situations and therefore calculating the ethical impossibility to withheld NIV in later stages of RF. Moreover, our hypotheses for sample size calculation might retrospectively be considered to have been too optimistic, and therefore our patient number is clearly limited and data have to be substantiated in a larger patient cohort. Generally, it must be envisioned, that early application of NIV in allogeneic transplant recipients may be of help but has to be combined with other modern treatment modalities for patients suffering from RF after HSCT.
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